ID   KK47/ADM
AC   CVCL_8254
DR   Wikidata; Q54899981
RX   PubMed=1353119;
RX   PubMed=29732388;
CC   Population: Japanese.
CC   Doubling time: 30 hours (PubMed=1353119).
CC   Selected for resistance to: ChEBI; CHEBI_28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_8253 ! KK47
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 13
//
RX   PubMed=1353119; DOI=10.1016/S0022-5347(17)36624-7;
RA   Kimiya K., Naito S., Soejima T., Sakamoto N., Kotoh S., Kumazawa J.,
RA   Tsuruo T.;
RT   "Establishment and characterization of doxorubicin-resistant human
RT   bladder cancer cell line, KK47/ADM.";
RL   J. Urol. 148:441-445(1992).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167; PMCID=PMC5929350;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//